These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 16498255)

  • 21. Role of Rifaximin in Inflammatory Bowel Disease Treatment.
    Scribano ML
    Mini Rev Med Chem; 2015; 16(3):225-9. PubMed ID: 26202194
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Probiotics for inflammatory bowel disease: a critical appraisal.
    Sans M
    Dig Dis; 2009; 27 Suppl 1():111-4. PubMed ID: 20203506
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Review article: antibiotics and probiotics in inflammatory bowel disease.
    Kruis W
    Aliment Pharmacol Ther; 2004 Oct; 20 Suppl 4():75-8. PubMed ID: 15352898
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evidence for the use of probiotics and prebiotics in inflammatory bowel disease: a review of clinical trials.
    Hedin C; Whelan K; Lindsay JO
    Proc Nutr Soc; 2007 Aug; 66(3):307-15. PubMed ID: 17637082
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Management of inflammatory bowel disease.
    Botoman VA; Bonner GF; Botoman DA
    Am Fam Physician; 1998 Jan; 57(1):57-68, 71-2. PubMed ID: 9447214
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antibiotics for inflammatory bowel disease: do they work?
    Guslandi M
    Eur J Gastroenterol Hepatol; 2005 Feb; 17(2):145-7. PubMed ID: 15674090
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Trichuris suis seems to be safe and possibly effective in the treatment of inflammatory bowel disease.
    Summers RW; Elliott DE; Qadir K; Urban JF; Thompson R; Weinstock JV
    Am J Gastroenterol; 2003 Sep; 98(9):2034-41. PubMed ID: 14499784
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Probiotics and antibiotics in inflammatory bowel disease.
    Gionchetti P; Rizzello F; Campieri M
    Curr Opin Gastroenterol; 2001 Jul; 17(4):331-5. PubMed ID: 17031179
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Topical delivery of therapeutic agents in the treatment of inflammatory bowel disease.
    Klotz U; Schwab M
    Adv Drug Deliv Rev; 2005 Jan; 57(2):267-79. PubMed ID: 15555742
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inflammatory bowel disease in children: a pediatrician's perspective.
    Cuffari C
    Minerva Pediatr; 2006 Apr; 58(2):139-57. PubMed ID: 16835574
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Role of intestinal flora in inflammatory bowel disease and probiotics place in their management].
    Belkahla N; Maamouri N; Ouerghi H; Ben Ammar A
    Tunis Med; 2005 Mar; 83(3):132-6. PubMed ID: 15929439
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Review article: the effects of antitumour necrosis factor-α on bone metabolism in inflammatory bowel disease.
    Veerappan SG; O'Morain CA; Daly JS; Ryan BM
    Aliment Pharmacol Ther; 2011 Jun; 33(12):1261-72. PubMed ID: 21521250
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunosuppressive therapy in pediatric inflammatory bowel disease: results of a survey of the North American Society for Pediatric Gastroenterology and Nutrition. Subcommittee on Immunosuppressive Use of the Pediatric IBD Collaborative Research Forum.
    Markowitz J; Grancher K; Mandel F; Daum F
    Am J Gastroenterol; 1993 Jan; 88(1):44-8. PubMed ID: 8420272
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Careful patient selection may improve response rates to infliximab in inflammatory bowel disease.
    Pearce CB; Lawrance IC
    J Gastroenterol Hepatol; 2007 Oct; 22(10):1671-7. PubMed ID: 17845695
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Selecting appropriate anti-TNF agents in inflammatory bowel disease.
    Yun L; Hanauer S
    Expert Rev Gastroenterol Hepatol; 2009 Jun; 3(3):235-48. PubMed ID: 19485806
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Review article: the potential mechanisms of action of rifaximin in the management of inflammatory bowel diseases.
    Sartor RB
    Aliment Pharmacol Ther; 2016 Jan; 43 Suppl 1():27-36. PubMed ID: 26618923
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Advances in inflammatory bowel diseases in children.
    Michail S; Ramsy M; Soliman E
    Minerva Pediatr; 2012 Jun; 64(3):257-70. PubMed ID: 22555319
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bacteriotherapy for inflammatory bowel disease: therapeutic tool and/or pharmacological vectors?
    Marteau P; Sokol H; Dray X; Seksik P
    Gastroenterol Clin Biol; 2009 Jun; 33 Suppl 3():S228-34. PubMed ID: 20117346
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The intriguing role of Rifaximin in gut barrier chronic inflammation and in the treatment of Crohn's disease.
    Lopetuso LR; Napoli M; Rizzatti G; Gasbarrini A
    Expert Opin Investig Drugs; 2018 Jun; 27(6):543-551. PubMed ID: 29865875
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Diagnostic problems and advances in inflammatory bowel disease.
    Odze R
    Mod Pathol; 2003 Apr; 16(4):347-58. PubMed ID: 12692200
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.